Amplification of neurotoxic HTTex1 assemblies in human neurons.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
11 2021
Historique:
received: 20 07 2021
revised: 24 08 2021
accepted: 21 09 2021
pubmed: 27 9 2021
medline: 5 3 2022
entrez: 26 9 2021
Statut: ppublish

Résumé

Huntington's disease (HD) is a genetically inherited neurodegenerative disorder caused by expansion of a polyglutamine (polyQ) repeat in the exon-1 of huntingtin protein (HTT). The expanded polyQ enhances the amyloidogenic propensity of HTT exon 1 (HTTex1), which forms a heterogeneous mixture of assemblies with a broad neurotoxicity spectrum. While predominantly intracellular, monomeric and aggregated mutant HTT species are also present in the cerebrospinal fluids of HD patients, however, their biological properties are not well understood. To explore the role of extracellular mutant HTT in aggregation and toxicity, we investigated the uptake and amplification of recombinant HTTex1 assemblies in cell culture models. We find that small HTTex1 fibrils preferentially enter human neurons and trigger the amplification of neurotoxic assemblies; astrocytes or epithelial cells are not permissive. The amplification of HTTex1 in neurons depletes endogenous HTT protein with non-pathogenic polyQ repeat, activates apoptotic caspase-3 pathway and induces nuclear fragmentation. Using a panel of novel monoclonal antibodies and genetic mutation, we identified epitopes within the N-terminal 17 amino acids and proline-rich domain of HTTex1 to be critical in neural uptake and amplification. Synaptosome preparations from the brain homogenates of HD mice also contain mutant HTT species, which enter neurons and behave similar to small recombinant HTTex1 fibrils. These studies suggest that amyloidogenic extracellular mutant HTTex1 assemblies may preferentially enter neurons, propagate and promote neurodegeneration.

Identifiants

pubmed: 34563643
pii: S0969-9961(21)00266-7
doi: 10.1016/j.nbd.2021.105517
pmc: PMC8943833
mid: NIHMS1745043
pii:
doi:

Substances chimiques

Amyloidogenic Proteins 0
HTT protein, human 0
Huntingtin Protein 0
Peptides 0
polyglutamine 26700-71-0
Caspase 3 EC 3.4.22.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105517

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS084345
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS118859
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Références

Acta Neuropathol. 2019 Jun;137(6):981-1001
pubmed: 30788585
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12784-9
pubmed: 11675509
Elife. 2020 Jan 15;9:
pubmed: 31939740
J Biol Chem. 2018 Feb 16;293(7):2597-2605
pubmed: 29282287
Nat Commun. 2020 Nov 19;11(1):5989
pubmed: 33214567
Nature. 2004 Oct 14;431(7010):805-10
pubmed: 15483602
N Engl J Med. 2019 Jun 13;380(24):2307-2316
pubmed: 31059641
PLoS One. 2012;7(7):e41794
pubmed: 22848609
Nat Commun. 2021 Jul 13;12(1):4272
pubmed: 34257293
Structure. 2019 Oct 1;27(10):1570-1580.e4
pubmed: 31466833
J Biol Chem. 2012 Sep 14;287(38):31739-46
pubmed: 22801429
J Cell Biol. 2019 Jun 3;218(6):1972-1993
pubmed: 31076452
J Neurosci. 2021 Jan 27;41(4):780-796
pubmed: 33310753
Sci Rep. 2018 Jun 29;8(1):9817
pubmed: 29959348
Nat Neurosci. 2018 Oct;21(10):1341-1349
pubmed: 30258241
PLoS One. 2009 Jun 02;4(6):e5768
pubmed: 19488402
J Vis Exp. 2008 Jul 16;(17):
pubmed: 19066511
J Neurosci. 2017 Sep 13;37(37):9000-9012
pubmed: 28821645
Hum Mol Genet. 2018 Jul 1;27(13):2330-2343
pubmed: 29912367
FEBS Lett. 2015 Jul 8;589(15):1897-903
pubmed: 26037141
Biochemistry. 2017 Jul 18;56(28):3579-3586
pubmed: 28621522
Nat Commun. 2018 Sep 27;9(1):3955
pubmed: 30262848
Handb Clin Neurol. 2018;147:255-278
pubmed: 29325616
Cell. 1997 Aug 8;90(3):537-48
pubmed: 9267033
Neuron. 2016 Mar 2;89(5):910-26
pubmed: 26938440
J Biol Chem. 2012 May 4;287(19):16017-28
pubmed: 22433867
Sci Rep. 2020 Nov 20;10(1):20295
pubmed: 33219289
Hum Mol Genet. 2017 Jan 15;26(2):395-406
pubmed: 28017939
Mol Cell. 2002 Aug;10(2):259-69
pubmed: 12191472
Mol Psychiatry. 2015 Nov;20(11):1286-93
pubmed: 26100538
Nat Commun. 2015 Apr 13;6:6768
pubmed: 25866135
EMBO J. 2006 Dec 13;25(24):5896-906
pubmed: 17124493
Mol Cell. 2018 Sep 6;71(5):675-688.e6
pubmed: 30193095
Cold Spring Harb Perspect Med. 2018 Feb 1;8(2):
pubmed: 28096245
Hum Mol Genet. 2010 Jan 1;19(1):65-78
pubmed: 19825844
Sci Rep. 2016 Jan 13;6:19180
pubmed: 26757959
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Ann Neurol. 2019 Feb;85(2):296-301
pubmed: 30549309
Cell. 2017 Sep 21;171(1):179-187.e10
pubmed: 28890085
J Neurochem. 2019 Nov;151(4):507-519
pubmed: 31418858
Elife. 2016 Oct 18;5:
pubmed: 27751235
Mol Cell. 2016 Sep 15;63(6):951-64
pubmed: 27570076
Science. 1997 Sep 26;277(5334):1990-3
pubmed: 9302293
Biochemistry. 2015 Jun 30;54(25):3942-9
pubmed: 26020223
PLoS One. 2016 Jun 06;11(6):e0155747
pubmed: 27271685
Nat Rev Dis Primers. 2015 Apr 23;1:15005
pubmed: 27188817
Elife. 2019 Apr 17;8:
pubmed: 30994454

Auteurs

Anjalika Chongtham (A)

Biology and Bioengineering, Caltech, Pasadena, CA 91125, USA.

J Mario Isas (JM)

Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA 90089, USA.

Nitin K Pandey (NK)

Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA 90089, USA.

Anoop Rawat (A)

Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA 90089, USA.

Jung Hyun Yoo (JH)

Biology and Bioengineering, Caltech, Pasadena, CA 91125, USA.

Tara Mastro (T)

Biology and Bioengineering, Caltech, Pasadena, CA 91125, USA.

Mary B Kennedy (MB)

Biology and Bioengineering, Caltech, Pasadena, CA 91125, USA.

Ralf Langen (R)

Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA 90089, USA.

Ali Khoshnan (A)

Biology and Bioengineering, Caltech, Pasadena, CA 91125, USA. Electronic address: Khoshnan@caltech.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH